Cargando…
Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer
PURPOSE: Bladder cancer (BCa) is one of the most common malignant tumors in the urogenital system, characterized by the high recurrence rate, mortality rate and poor prognosis. Based on cuproptosis-related long noncoding RNAs (CRLs), this study set out to create a prediction signature to evaluate th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715909/ https://www.ncbi.nlm.nih.gov/pubmed/36454396 http://dx.doi.org/10.1007/s12672-022-00596-w |
_version_ | 1784842561759739904 |
---|---|
author | Chen, Jia Guan, Yu Li, Chun Du, Hexi Liang, Chaozhao |
author_facet | Chen, Jia Guan, Yu Li, Chun Du, Hexi Liang, Chaozhao |
author_sort | Chen, Jia |
collection | PubMed |
description | PURPOSE: Bladder cancer (BCa) is one of the most common malignant tumors in the urogenital system, characterized by the high recurrence rate, mortality rate and poor prognosis. Based on cuproptosis-related long noncoding RNAs (CRLs), this study set out to create a prediction signature to evaluate the prognosis of patients with BCa. METHODS: RNA-seq data including CRLs and related clinicopathological data were gathered from The Cancer Genome Atlas (TCGA) database (n = 428). The predictive signature was constructed after correlation analysis. Subsequently, relying on the analyzed data from the TCGA database and our sample collection, we examined and verified the connections between CRLs model and important indexes included prognosis, route and functional enrichment, tumor immune evasion, tumor mutation, and treatment sensitivity. RESULTS: Patients in the high-risk group had lower overall survival (OS) than that of low-risk group. Compared with clinicopathological variables, CRLs features have better predictive value according to receiver operating characteristic (ROC) curve. The expression level of CRLs was highly associated with the tumor progress, tumor microenvironment and tumor immune escape. Additionally, we identified that the mutation of TP53, TTN, KMT2D and MUC16 gene were founded in patients with BCa. Lapatinib, pazopanib, saracatinib, gemcitabine, paclitaxel and palenolactone had good antitumor effects for BCa patients in the high-risk group (all P < 0.001). CONCLUSION: This study revealed the effects of CRLs on BCa and further established CRLs model, which can be used in clinic for predicting prognosis, immunological response and treatment sensitivity inpatient with BCa. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-022-00596-w. |
format | Online Article Text |
id | pubmed-9715909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-97159092022-12-03 Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer Chen, Jia Guan, Yu Li, Chun Du, Hexi Liang, Chaozhao Discov Oncol Research PURPOSE: Bladder cancer (BCa) is one of the most common malignant tumors in the urogenital system, characterized by the high recurrence rate, mortality rate and poor prognosis. Based on cuproptosis-related long noncoding RNAs (CRLs), this study set out to create a prediction signature to evaluate the prognosis of patients with BCa. METHODS: RNA-seq data including CRLs and related clinicopathological data were gathered from The Cancer Genome Atlas (TCGA) database (n = 428). The predictive signature was constructed after correlation analysis. Subsequently, relying on the analyzed data from the TCGA database and our sample collection, we examined and verified the connections between CRLs model and important indexes included prognosis, route and functional enrichment, tumor immune evasion, tumor mutation, and treatment sensitivity. RESULTS: Patients in the high-risk group had lower overall survival (OS) than that of low-risk group. Compared with clinicopathological variables, CRLs features have better predictive value according to receiver operating characteristic (ROC) curve. The expression level of CRLs was highly associated with the tumor progress, tumor microenvironment and tumor immune escape. Additionally, we identified that the mutation of TP53, TTN, KMT2D and MUC16 gene were founded in patients with BCa. Lapatinib, pazopanib, saracatinib, gemcitabine, paclitaxel and palenolactone had good antitumor effects for BCa patients in the high-risk group (all P < 0.001). CONCLUSION: This study revealed the effects of CRLs on BCa and further established CRLs model, which can be used in clinic for predicting prognosis, immunological response and treatment sensitivity inpatient with BCa. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-022-00596-w. Springer US 2022-12-01 /pmc/articles/PMC9715909/ /pubmed/36454396 http://dx.doi.org/10.1007/s12672-022-00596-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Chen, Jia Guan, Yu Li, Chun Du, Hexi Liang, Chaozhao Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer |
title | Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer |
title_full | Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer |
title_fullStr | Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer |
title_full_unstemmed | Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer |
title_short | Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer |
title_sort | identification and validation of a novel cuproptosis-related lncrna gene signature to predict prognosis and immune response in bladder cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715909/ https://www.ncbi.nlm.nih.gov/pubmed/36454396 http://dx.doi.org/10.1007/s12672-022-00596-w |
work_keys_str_mv | AT chenjia identificationandvalidationofanovelcuproptosisrelatedlncrnagenesignaturetopredictprognosisandimmuneresponseinbladdercancer AT guanyu identificationandvalidationofanovelcuproptosisrelatedlncrnagenesignaturetopredictprognosisandimmuneresponseinbladdercancer AT lichun identificationandvalidationofanovelcuproptosisrelatedlncrnagenesignaturetopredictprognosisandimmuneresponseinbladdercancer AT duhexi identificationandvalidationofanovelcuproptosisrelatedlncrnagenesignaturetopredictprognosisandimmuneresponseinbladdercancer AT liangchaozhao identificationandvalidationofanovelcuproptosisrelatedlncrnagenesignaturetopredictprognosisandimmuneresponseinbladdercancer |